CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	December 2023 Warrant Exchange	Public Offering	Nonrelated Party	Common Stock	Common Stock Public Offering	Common Stock Nonrelated Party	Additional Paid-In Capital	Additional Paid-In Capital December 2023 Warrant Exchange	Additional Paid-In Capital Public Offering	Additional Paid-In Capital Nonrelated Party	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Series 9 Preferred Stock	Series 9 Preferred Stock Series 9 Preferred Stock at Redemption Value	Series 9 Preferred Stock Common Stock	Series 9 Preferred Stock Additional Paid-In Capital
Balance, beginning (in shares) at Dec. 31, 2022															0
Balance, beginning (in shares) at Dec. 31, 2022					3,181,578
Balance, beginning at Dec. 31, 2022	$ (14,982)				$ 3			$ 17,908				$ 0	$ (32,893)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(1,565)												(1,565)
Stock-based compensation	141							141
Issuance of warrants with convertible note	39							39
Balance, ending (in shares) at Mar. 31, 2023															0
Balance, ending at Mar. 31, 2023	(16,367)				$ 3			18,088				0	(34,458)		$ 0
Balance, ending (in shares) at Mar. 31, 2023					3,181,578
Balance, beginning (in shares) at Dec. 31, 2022															0
Balance, beginning (in shares) at Dec. 31, 2022					3,181,578
Balance, beginning at Dec. 31, 2022	(14,982)				$ 3			17,908				0	(32,893)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,897)
Change in fair value of convertible note receivable	0
Balance, ending (in shares) at Sep. 30, 2023															0
Balance, ending at Sep. 30, 2023	(14,339)				$ 3			27,448				0	(41,790)		$ 0
Balance, ending (in shares) at Sep. 30, 2023					3,197,573
Balance, beginning (in shares) at Mar. 31, 2023															0
Balance, beginning (in shares) at Mar. 31, 2023					3,181,578
Balance, beginning at Mar. 31, 2023	(16,367)				$ 3			18,088				0	(34,458)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (4,629)												(4,629)
Stock issued during period, shares, new issues (in shares)	12,853
Stock issued during period, value, new issues	$ 180							180
Stock-based compensation	2,461							2,461
Issuance of warrants with convertible note	928							928
JV obligation reclassified to equity	5,583
Balance, ending (in shares) at Jun. 30, 2023															0
Balance, ending at Jun. 30, 2023	(11,844)				$ 3			27,240				0	(39,087)		$ 0
Balance, ending (in shares) at Jun. 30, 2023					3,194,431
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (2,703)												(2,703)
Stock issued during period, shares, new issues (in shares)	3,142
Stock issued during period, value, new issues	$ 44							44
Stock-based compensation	164							164
Change in fair value of convertible note receivable	0
Balance, ending (in shares) at Sep. 30, 2023															0
Balance, ending at Sep. 30, 2023	$ (14,339)				$ 3			27,448				0	(41,790)		$ 0
Balance, ending (in shares) at Sep. 30, 2023					3,197,573
Balance, beginning (in shares) at Dec. 31, 2023														0	0
Balance, beginning (in shares) at Dec. 31, 2023	3,197,771				3,197,771
Balance, beginning at Dec. 31, 2023	$ (31,629)				$ 3			26,327				0	(57,959)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for conversion of convertible securities (in shares)							2,887,788
Stock issued during period, value, conversion of convertible securities				$ 9,614			$ 3				$ 9,611
Inducement loss on debt conversions	6,732							6,732
Common stock issued to Xeriant, Inc. (in shares)					298,395
Common stock issued for exercise of warrants (in shares)					482,015
Common shares issued for cashless exercise of warrants and options	0				$ 1			(1)
Common and preferred shares issued via merger (in shares)					2,075,743										11,302
Common and preferred shares issued via merger	25,605				$ 2			14,301							$ 11,302
Capital contribution - forgiveness of related party payable	380							380
Stock based compensation (in shares)					977,699
Stock-based compensation	5,792				$ 1			5,791
Cumulative translation adjustment	(166)											(166)
Series 9 preferred stock dividend accrued	(61)							(61)
Net loss	(2,602)												(2,602)
Balance, ending (in shares) at Mar. 31, 2024															11,302
Balance, ending at Mar. 31, 2024	$ 13,665				$ 10			63,080				(166)	(60,561)		$ 11,302
Balance, ending (in shares) at Mar. 31, 2024					9,919,411
Balance, beginning (in shares) at Dec. 31, 2023														0	0
Balance, beginning (in shares) at Dec. 31, 2023	3,197,771				3,197,771
Balance, beginning at Dec. 31, 2023	$ (31,629)				$ 3			26,327				0	(57,959)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(21,747)
Change in fair value of convertible note receivable	59
Balance, ending (in shares) at Sep. 30, 2024														6,677	6,677
Balance, ending at Sep. 30, 2024	$ 6,865				$ 38			79,332				524	(79,706)		$ 6,677
Balance, ending (in shares) at Sep. 30, 2024	38,008,995				38,008,995
Balance, beginning (in shares) at Mar. 31, 2024															11,302
Balance, beginning (in shares) at Mar. 31, 2024					9,919,411
Balance, beginning at Mar. 31, 2024	$ 13,665				$ 10			63,080				(166)	(60,561)		$ 11,302
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for conversion of convertible securities (in shares)															(3,550)	2,999,187
Stock issued during period, value, conversion of convertible securities														$ 177	$ (3,550)	$ 3	$ 3,724
Stock-based compensation	(59)							(59)
Cumulative translation adjustment	(32)											(32)
Series 9 preferred stock dividend accrued	(250)							(250)
Net loss	(14,710)												(14,710)
Deemed dividend related to Series 9 preferred stock exchange														$ (177)			(177)
Common shares issued in exchange of warrants (in shares)					1,492,415
Common shares issued in exchange of warrants	1,981				$ 2			1,979
Deemed dividend related to December 2023 warrant exchange		$ (283)							$ (283)
Common shares issued in exchange of warrants (in shares)					20,528
Common shares issued for exercise of warrants	2							2
Stock issued during period, shares, new issues (in shares)						9,300,203
Stock issued during period, value, new issues			$ 8,675			$ 9				$ 8,666
Common shares issued as settlement of accrued compensation (in shares)					2,680,459
Common shares issued as settlement of accrued compensation	1,192				$ 3			1,189
Common shares issued as prepayment for marketing services (in shares)					429,483
Common shares issued as prepayment for services	335							335
Change in fair value of convertible note receivable	59											59
Balance, ending (in shares) at Jun. 30, 2024															7,752
Balance, ending at Jun. 30, 2024	10,575				$ 27			78,206				(139)	(75,271)		$ 7,752
Balance, ending (in shares) at Jun. 30, 2024					26,841,686
Balance, beginning (in shares) at Mar. 31, 2024															11,302
Balance, beginning (in shares) at Mar. 31, 2024					9,919,411
Balance, beginning at Mar. 31, 2024	13,665				$ 10			63,080				(166)	(60,561)		$ 11,302
Balance, ending (in shares) at Sep. 30, 2024														6,677	6,677
Balance, ending at Sep. 30, 2024	$ 6,865				$ 38			79,332				524	(79,706)		$ 6,677
Balance, ending (in shares) at Sep. 30, 2024	38,008,995				38,008,995
Balance, beginning (in shares) at Jun. 30, 2024															7,752
Balance, beginning (in shares) at Jun. 30, 2024					26,841,686
Balance, beginning at Jun. 30, 2024	$ 10,575				$ 27			78,206				(139)	(75,271)		$ 7,752
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for conversion of convertible securities (in shares)															(1,075)	4,196,813
Stock issued during period, value, conversion of convertible securities														$ 54	$ (1,075)	$ 4	1,125
Stock based compensation (in shares)					1,004,886
Stock-based compensation	(1,889)				$ 1			(1,890)
Cumulative translation adjustment	663											663
Series 9 preferred stock dividend accrued	(185)							(185)
Net loss	(4,435)												(4,435)
Deemed dividend related to Series 9 preferred stock exchange														$ (54)			$ (54)
Stock issued during period, shares, new issues (in shares)						3,190,727
Stock issued during period, value, new issues			$ 1,035			$ 3				$ 1,032
Common shares issued as settlement of accrued compensation (in shares)					2,774,883
Common shares issued as settlement of accrued compensation	1,101				$ 3			1,098
Change in fair value of convertible note receivable	0
Balance, ending (in shares) at Sep. 30, 2024														6,677	6,677
Balance, ending at Sep. 30, 2024	$ 6,865				$ 38			$ 79,332				$ 524	$ (79,706)		$ 6,677
Balance, ending (in shares) at Sep. 30, 2024	38,008,995				38,008,995